For those in healthcare. By those in healthcare.

HHS advances pathogen reduction technologies for blood products

Two pathogen reduction device technologies that may help reduce the risk of transmitting disease through blood product transfusions, including those diseases related to Zika virus, will advance in development with the support of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). 

The development of these technologies to treat red blood cells will be funded through contracts with ASPR’s Biomedical Advanced Research and Development Authority (BARDA) as part of BARDA’s ongoing efforts to advance new medical products to protect the nation’s health from emerging infectious diseases or chemical, biological, radiological or nuclear (CBRN) threats, particularly for radiological or nuclear mass casualty incidents requiring the use of blood products.

“We are working to make needed products available as quickly as possible to protect our nation’s blood supply against a variety of threats that could endanger public health,” said Dr. Richard Hatchett, BARDA’s acting director. “These technologies are of particular interest given their potential use against multiple diseases. By focusing on products that can reduce the risk of various transfusion-transmitted infections, we can provide emergency products sooner in a sustainable, cost-effective way.”

To continue reading this article…

Start your monthly or annual subscription to HIT Leaders & News today!

A monthly Standard subscription to all our regular news articles costs only $12.00 per month, or $144.00 for an annual Standard subscription.

Already a subscriber? Log in


BARDA, Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Government Perspectives, HHS, INTERCEPT system, pathogen reduction, Zika


Please follow and ‘Like’ us


©2021 HIT Leaders and News, a GO Digital Media publication. All rights reserved.